Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has been assigned an average recommendation of “Hold” from the twenty-three research firms that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $42.93.
Several analysts recently commented on the company. Mizuho cut Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $53.00 to $44.00 in a report on Wednesday, November 29th. HC Wainwright set a $55.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Canaccord Genuity set a $46.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Royal Bank of Canada set a $54.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.60% of the stock is currently owned by corporate insiders.
Shares of Pacira Pharmaceuticals (PCRX) opened at $31.90 on Friday. Pacira Pharmaceuticals has a twelve month low of $29.35 and a twelve month high of $52.47. The company has a market capitalization of $1,290.00, a P/E ratio of -29.27 and a beta of 1.95. The company has a quick ratio of 6.24, a current ratio of 6.96 and a debt-to-equity ratio of 0.99.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same period in the prior year, the business posted $0.09 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. equities analysts predict that Pacira Pharmaceuticals will post -0.24 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2018/03/17/pacira-pharmaceuticals-inc-pcrx-receives-average-rating-of-hold-from-brokerages.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.